Abstract
Two guidelines for the management of people with asthma are available in the UK, the British Thoracic Society (BTS)/Scottish Intercollegiate Guidelines Network (SIGN) and the National Institute for Health and Care Excellence (NICE). However, only NICE reviewed the health economic evidence. Differences between the two guidelines’ recommendations raise further issues when it comes to choosing value for money interventions. The aim of this article is to propose a cost-effectiveness value pyramid of asthma interventions in the UK guided by the available cost-utility evidence.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
